Beneath the surface of these discrete signals, a single structural tension is tightening. The pharmaceutical pathway and the decriminalization-plus-Indigenous-sovereignty pathway are no longer simply philosophically different — they are beginning to compete for the same legislative oxygen, the same public credibility, and ultimately the same patients. State-level therapeutic exemption bills are advancing precisely because federal scheduling creates a vacuum that states are constitutionally permitted to partially fill. And the question of who controls the protocols — trained clinicians operating under FDA-cleared pharmaceutical frameworks, or Indigenous and community practitioners whose epistemologies predate the clinical trial by centuries — is no longer an academic debate. At least one peer-reviewed effort to bridge these frameworks formally is in progress, and the insurance reimbursement question looms over both: without a path for coverage, the "real market size," as one analyst put it, remains theoretical. The field is revealing that it cannot resolve its access problem without first resolving its identity problem.
The people living inside these signals are not waiting for resolution. They are veterans whose TBI and PTSD have not responded to approved pharmacology, sitting with the knowledge that ibogaine or MDMA-assisted therapy showed them something irreversible about their own minds — and that the system treating them as a liability cannot yet offer what they have already experienced as a fact. They are Indigenous practitioners who have watched their medicines be extracted, patented in adjacent forms, and rebranded as breakthrough therapy without a syllable of acknowledgment. They are therapists who trained for this moment and cannot yet legally practice what they trained for. They are patients with treatment-resistant depression who have done the math on clinical trial waitlists and found the numbers do not work in their favor. What they are feeling is not impatience exactly — it is the particular exhaustion of people who already know the answer and are being asked to wait for the institution to catch up.
What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care.
The current is already moving. You are already in it.
88%
DEA keeps psilocybin and MDMA illegal through October 2026
The DEA (US drug enforcement agency) almost certainly will not change the legal status of magic mushrooms or MDMA in the next six months. That's because no approved medicine using these drugs exists yet, and rescheduling requires years of bureaucratic work.
→ Psilocybin and MDMA will stay federally illegal because there are no approved medicines yet to trigger the bureaucratic rescheduling process.
Resolves: 2026-10-30 · USA
LEGISLATION
the precise call ▾
DEA maintains Schedule I status for psilocybin and MDMA through October 2026 with no approved rescheduling petition. DEA rescheduling requires either an HHS recommendation or a petitioner-initiated process that historically takes years. FDA declined to approve MDMA-assisted therapy in 2024; psilocybin has no pending NDA. Without an approved NDA or extraordinary political intervention, DEA has no administrative tri
62%
Congress introduces a bipartisan bill supporting psychedelic research
At least one member of Congress from each major party will sponsor a bill aimed at expanding research funding or removing regulatory barriers for psychedelics. Introducing a bill is easy; passing it is hard. This matters because it signals that politicians see this research as legitimate.
→ Expect Congress to introduce a new bill supporting psychedelic research in the next six months, though it may not pass.
Resolves: 2026-10-30 · USA
LEGISLATION
the precise call ▾
A bipartisan psychedelic research bill is introduced in the U.S. Congress. Multiple bipartisan psychedelic research bills have been introduced in prior sessions (e.g., BREAKTHROUGH Act, Veterans bills). Introduction is a low bar—it requires only one sponsor from each party to co-sponsor. Given demonstrated congressional interest and veteran-advocacy momentum, introduction
42%
Congress introduces bill protecting Indigenous plant medicine and sovereignty rights
A legislator will formally introduce a bill that protects Indigenous peoples' ability to use traditional plant medicines like peyote, ayahuasca, or psilocybin in ceremonies, and recognizes tribal sovereignty over these practices. This matters because it validates Indigenous knowledge and potentially carves out legal space for traditional healing. But federal bills on this are rare.
→ Congress might introduce an Indigenous plant medicine bill, but it's an uphill fight and less likely than not in six months.
Resolves: 2026-10-30 · USA
LEGISLATION
the precise call ▾
A U.S. federal or state bill specifically addressing indigenous ceremonial plant medicine access or sovereignty is formally introduced. Bills addressing indigenous ceremonial peyote access have been introduced before (e.g., peyote exemptions for Native American Church). A broader bill covering ayahuasca, psilocybin mushrooms, or other plant medicines with explicit indigenous sovereignty framing is plausible but historically rare at
38%
One US state passes a psychedelic therapy or decriminalization law
A state legislature will vote and pass a bill allowing either regulated psilocybin therapy (like Oregon and Colorado did) or decriminalizing possession of psychedelics. This matters because it creates legal markets and proves the model works elsewhere. However, this is harder than just introducing a bill—the law must actually pass both chambers and be signed.
→ It's less likely than not that any state will pass a full psychedelic law in six months, given slow legislative cycles.
Resolves: 2026-10-30 · USA
LEGISLATION
the precise call ▾
At least one U.S. state legislature passes a psychedelic decriminalization or regulated therapeutic access bill. Oregon Measure 109 is operational; Colorado Prop 122 implementation is underway. Several states (California, Minnesota, Maryland, Nevada) have active bills. However, 'passes' means full legislative passage (both chambers where applicable) and governor signature or veto override—not merely committee
80%
MAPS or Compass publishes psilocybin trial safety or enrollment update
Two major psychedelic companies running government-approved depression trials must publicly share how their studies are going. This matters because it tells patients, doctors, and investors whether magic mushroom therapy actually works and is safe.
→ Two companies racing to get magic mushroom therapy approved must tell the world how their trials are progressing in the next six months.
Resolves: 2026-10-30 · USA
RESEARCH
the precise call ▾
MAPS or Compass Pathways publishes Phase 3 psilocybin trial enrollment or safety data update. MAPS has ongoing Phase 3 psilocybin trials with breakthrough therapy designation, requiring periodic public disclosures to FDA and investors. Compass Pathways (COMP360) has already published Phase 3 data (2025) and may release follow-up analyses. Enrollment and safety updates are mandatory for break
55%
Compass or MAPS announces Phase 3 results or FDA pre-approval meeting
One of the two leading companies will announce new data showing how well their psilocybin therapy works, or announce a formal meeting with the FDA to discuss approval. Compass already reported results; MAPS is earlier. Either company sharing next-step news matters because it moves closer to actual FDA approval.
→ One company will likely announce Phase 3 data or an FDA meeting in the next six months, but it's not a sure bet.
Resolves: 2026-10-30 · USA
RESEARCH
the precise call ▾
MAPS or Compass Pathways publicly announces Phase 3 psilocybin efficacy data or a formal FDA pre-approval meeting. Compass Pathways has already reported primary Phase 3 COMP360 results (published late 2025). A follow-up analysis, secondary endpoint publication, or FDA Type C/pre-NDA meeting announcement within six months is plausible but not certain—Compass's path forward depends on whether they pursue an NDA gi
8%
US insurer or Medicare announces psychedelic therapy reimbursement guidance
CMS (Centers for Medicare and Medicaid Services, which runs Medicare) or a major insurance company announces they will pay for psilocybin or MDMA therapy. This would be huge for patients and companies. But it almost won't happen in six months because the FDA hasn't approved any psychedelic medicine yet, and insurers won't pay for unapproved drugs.
→ No insurer will announce psychedelic reimbursement because no psychedelic medicine is FDA-approved yet.
Resolves: 2026-10-30 · USA
MARKET
the precise call ▾
A U.S. insurer, CMS, or federal agency issues formal guidance or announces a pilot program for psychedelic-assisted therapy reimbursement. No psychedelic-assisted therapy is currently FDA-approved in the U.S. (MDMA was rejected; psilocybin has no NDA). Without an approved product, CMS and private insurers have no regulatory basis for coverage guidance. 'Pilot program' or 'guidance' must be a formal, public, binding or semi-binding docu